Abstract
GEP analysis is a robust method to distinguish low- and high-risk multiple myeloma (MM), pertaining to 85% and 15% of newly diagnosed patients, respectively (Shaughnessy et al., Blood, 2007; 109:2276–84). As developed in TT2 and validated in TT3A and TT3B, we are now examining, similar to previous work in high-risk MM, whether we can define outliers among low-risk MM, i.e., patients not living up to the low-risk prediction model. Toward this end, we scrutinized early relapses in TT3A and TT3B within three years of protocol entry. Using logistic regression analysis, we identified baseline parameters including GEP, en route for distinguishing this high-risk subset among low-risk MM. Also examined was whether a new model could be built within low-risk disease that allowed for the identification of a high-risk subset. Our database was interrogated for patients known to have GEP-defined low-risk in the GEP-70 model. Table 1 summarizes the 3-year events among GEP-70 low-risk subjects per protocol. An optimal cut-point at +0.146 distinguished, among the combined TT2 and TT3 patients, inferior progression-free survival (PFS) and overall survival (OS) (Figure 1a). Next, we examined outcomes among all TT2 and TT3 patients with GEP data, including those with traditionally-defined high-risk (>=0.66). Here, we were able to distinguish three subgroups with distinctly different PFS and OS (Figure 1b). Utilizing logistic regression analysis, limited to traditionally-defined GEP-70 low-risk MM (=<0.66), three-year progression events during the this period were adversely dominated by the following: GEP-70 scores >0.146 (HR=2.61, p=0.0005), the presence of cytogenetic abnormalities (CA) (HR=1.93, p=0.018), B2M >5.5mg/L (HR=1.95, p=0.04) and LDH >190U/L (HR=1.93, 0.02). These are all reported in Table 2. In conclusion, we have identified, within GEP-70 low-risk patients, a new cut-point. This allows a better categorization of patients having truly low risk disease. Also, above which a prognosis intermediate to the traditional high-risk prognostic group (>=0.66) could be identified. GEP >0.146 dominated a multivariate logistic regression model. Further efforts will be presented on unique genes characterizing this intermediate risk group in relationship to low and high-risk subsets.
Protocol . | Total with GEP . | GEP-70 low-risk . | GEP-70 low-risk, event within first 3 years . |
---|---|---|---|
TT2 - thalidomide | 176 | 156 | 55 |
TT2 + thalidomide | 175 | 149 | 36 |
TT3A | 275 | 235 | 39 |
TT3B | 166 | 129 | 23 |
Protocol . | Total with GEP . | GEP-70 low-risk . | GEP-70 low-risk, event within first 3 years . |
---|---|---|---|
TT2 - thalidomide | 176 | 156 | 55 |
TT2 + thalidomide | 175 | 149 | 36 |
TT3A | 275 | 235 | 39 |
TT3B | 166 | 129 | 23 |
. | Event in first three years on protocol . | |||||
---|---|---|---|---|---|---|
Variable . | N . | With Factor . | Without Factor . | OR (95% CI) . | P - value . | |
Multivariate | B2M > 5.5 mg/L | 666 | 24/69 (35%) | 59/328 (18%) | 1.95 (1.03, 3.69) | 0.0401 |
LDH >= 190 U/L | 668 | 33/99 (33%) | 50/298 (17%) | 1.93 (1.10, 3.40) | 0.0229 | |
Cytogenetic abnormalities | 665 | 35/116 (30%) | 48/281 (17%) | 1.93 (1.12, 3.32) | 0.0182 | |
GEP-70 score > 0.146 | 669 | 37/104 (36%) | 46/293 (16%) | 2.61 (1.52, 4.47) | 0.0005 |
. | Event in first three years on protocol . | |||||
---|---|---|---|---|---|---|
Variable . | N . | With Factor . | Without Factor . | OR (95% CI) . | P - value . | |
Multivariate | B2M > 5.5 mg/L | 666 | 24/69 (35%) | 59/328 (18%) | 1.95 (1.03, 3.69) | 0.0401 |
LDH >= 190 U/L | 668 | 33/99 (33%) | 50/298 (17%) | 1.93 (1.10, 3.40) | 0.0229 | |
Cytogenetic abnormalities | 665 | 35/116 (30%) | 48/281 (17%) | 1.93 (1.12, 3.32) | 0.0182 | |
GEP-70 score > 0.146 | 669 | 37/104 (36%) | 46/293 (16%) | 2.61 (1.52, 4.47) | 0.0005 |
OR - Odds Ratio, 95% CI - 95% Confidence Interval, P - value from Wald Chi - Square Test in Logistic Regression.
NS2 - Multivariate results not statistically significant at 0.05 level. Univariate p - values reported regardless of significance.
Multivariate model uses stepwise selection with entry level 0.1 and variable remains if meets the 0.05 level.
A multivariate p - value greater than 0.05 indicates variable forced into model with significant variables chosen using stepwise selection.
No relevant conflicts of interest to declare.
This icon denotes a clinically relevant abstract
Author notes
Asterisk with author names denotes non-ASH members.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal